Form 4: Neurogene Inc. Insider Sells Shares Under 10b5-1 Plan

Neurogene Inc. reports insider Christine Cvijic sold shares valued at approximately $36 per share as part of a pre-arranged trading plan.

Summary

• Christine Cvijic, a Director and Officer (President and CFO) of Neurogene Inc., executed transactions involving the sale of company common stock.
• These sales occurred on July 6, 2026, and July 7, 2026.
• The transactions were conducted under a Rule 10b5-1 trading plan adopted on August 18, 2025.
• On July 6, 2026, 600 shares were sold at a weighted average price of $36.02.
• On July 7, 2026, 4,200 shares were sold at a weighted average price of $36.13.
• Following these sales, Cvijic beneficially owns 84,040 shares.
• The reported sales were jointly held with her spouse, David Cvijic, and following these sales, she no longer holds shares jointly with him.
• Cvijic also holds restricted stock units (RSUs) that are subject to future vesting schedules.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the execution of these sales under a pre-established Rule 10b5-1 plan mitigates concerns about opportunistic trading.

Positives

• Transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-impactful sales.
• The sales occurred at prices around $36 per share, suggesting a stable or potentially favorable valuation at the time of sale.
• Christine Cvijic retains a significant number of shares (84,040) after the reported transactions, indicating continued beneficial ownership.

Negatives

• Insider selling can sometimes be perceived negatively by the market, although this sale was conducted under a pre-arranged plan.
• The total number of shares sold is 4,800, which, while executed under a plan, represents a reduction in direct holdings by a key executive.

Risks

• The Rule 10b5-1 plan is designed to mitigate insider trading concerns, but the act of selling by a key executive could still be interpreted as a lack of confidence by some investors.
• Future vesting of restricted stock units could lead to further potential sales, depending on the terms of those grants and market conditions.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025.
• Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
• The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by Neurogene Inc.'s President and CFO is a common practice to allow executives to sell shares systematically without facing accusations of insider trading, especially in the biotechnology sector where stock price can be volatile.

Related Party Transactions

• Shares sold on July 6 and July 7, 2026, were held jointly by Christine Cvijic and her spouse, David Cvijic. Following these sales, joint ownership ceased.

Stakeholder Impact

• Shareholders: May interpret insider selling, even under a 10b5-1 plan, with caution, although the plan itself is a governance safeguard.
• Employees: May observe executive compensation and stock ownership trends.
• Management: Demonstrates adherence to compliance protocols for stock transactions.

Next Steps

• The reporting person will continue to hold restricted stock units with future vesting dates.
• The company may receive requests for further information regarding the specific prices of shares sold within the reported ranges.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Neurogene Inc., NGNE, Stock Sale, Beneficial Ownership, Christine Cvijic, Restricted Stock Units, SEC Filing